CTLA4 enhances the osteogenic differentiation of allogeneic human mesenchymal stem cells in a model of immune activation
Braz. j. med. biol. res
;
48(7): 629-636, 07/2015. graf
Article
in English
| LILACS
| ID: lil-751342
ABSTRACT
Allogeneic mesenchymal stem cells (allo-MSCs) have recently garnered increasing interest for their broad clinical therapy applications. Despite this, many studies have shown that allo-MSCs are associated with a high rate of graft rejection unless immunosuppressive therapy is administered to control allo-immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a co-inhibitory molecule expressed on T cells that mediates the inhibition of T-cell function. Here, we investigated the osteogenic differentiation potency of allo-MSCs in an activated immune system that mimics the in vivo allo-MSC grafting microenvironment and explored the immunomodulatory role of the helper T cell receptor CTLA4 in this process. We found that MSC osteogenic differentiation was inhibited in the presence of the activated immune response and that overexpression of CTLA4 in allo-MSCs suppressed the immune response and promoted osteogenic differentiation. Our results support the application of CTLA4-overexpressing allo-MSCs in bone tissue engineering.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Stroke Volume
/
Ventricular Function, Left
/
Echocardiography, Doppler, Color
/
Heart Failure
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. med. biol. res
Journal subject:
Biology
/
Medicine
Year:
2015
Type:
Article
/
Project document
Affiliation country:
China
Institution/Affiliation country:
Third Military Medical University/CN
Similar
MEDLINE
...
LILACS
LIS